Replies to post #130 on Equity Field Notes from temporal sources

[DanWebzster]

HRTX may have the best CEO in small-cap biotech.

Recent Ph3 results fro post-operative pain set it up for FDA approval and opioid-sparing status

PDUFA for post operative pain should be set for mid-2019.

CINV franchise is still growing. TSRO will stop promoting competing treatment, due to safety issues.

EOY/17 Cash = $172.4mn with AR = $41.8mn The high AR was due to a lack of J-code for CINV franchise.

Since EOY/17, HRTX acquired the J-code and raised $169mn in an offering.